Blu-945 is a potent inhibitor of selective epidermal growth factor receptor (EGFR). EGFR is a member of the erbB receptor family, which includes receptors for transmembrane protein tyrosine kinases. Blu-945 effectively inhibits EGFR with L858R and/or exon 19 deletion mutations, T790M mutations and C797S mutations. Blu-945 contributes to effective administration and reduces egFR-mediated targeted toxicity. Blu-945 has the potential to study cancer diseases (information extracted from patent WO2021133809A1, compound 112).
Molecular Weight | 556.7 |
Formula | C28H37FN6O3S |
CAS Number | 2660250-10-0 |
Solubility (25°C) | N/A |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related EGFR/HER2 Products |
---|
Dosimertinib
Dosimertinib is a highly potent, selective, orally effective EGFR inhibitor for the study of non-small cell lung cancer. |
JBJ-09-063
JBJ-09-063 is an oral allogenic epidermal growth factor inhibitor currently in preclinical development for the study of non-small cell lung cancer (NSCLC) with epidermal growth factor L858R mutations. |
BI-4142
BI-4142 is a HER2 exon 20 insertion mutant inhibitor being developed for non-small cell lung cancer (NSCLC), The IC50 value was 5 nM. |
BDTX-189
BDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations with Kd of 0.2 nM, 0.76 nM, 13 nM and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. BDTX-189 exhibits anticancer activity. |
Naquotinib(ASP8273)
Naquotinib(ASP8273) is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.